Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial

J. J. Belch, J. Cormie, P. Newman, M. McLaren, J. Barbenel, H. Capell, P. Leiberman, C. D. Forbes, C. R. Prentice

    Research output: Contribution to journalArticle

    30 Citations (Scopus)

    Abstract

    1 UK-37248 (dazoxiben), an orally active thromboxane synthetase inhibitor, was evaluated in a double-blind trial of patients with severe Raynaud's syndrome. 2 Twenty patients were enrolled in the study. Eleven of these patients received dazoxiben 400 mg day and nine received matching placebo capsules. Treatment was given for 6 weeks and the patients reviewed at 2 weekly intervals during the study. 3 Assessment of response was judged by clinical symptoms and hand temperature measurements. Haematological and haemostatic studies were also carried out. 4 Results show a significant clinical improvement in patients receiving dazoxiben for six weeks. Hand temperature measurements, and haematological and haemostatic blood tests remained unchanged, however, apart from the expected lowering in plasma thromboxane B2 levels. 5 The mechanism of action of the drug would appear not to be mediated through increased prostacyclin production and further studies are under way to determine how improvement has been obtained in these patients.
    Original languageEnglish
    Pages (from-to)113S-116S
    Number of pages4
    JournalBritish Journal of Clinical Pharmacology
    Volume15
    Issue numberS1
    DOIs
    Publication statusPublished - 1983

    Fingerprint

    Thromboxane-A Synthase
    Hemostatics
    Therapeutics
    Hand
    Thromboxane B2
    Temperature
    Hematologic Tests
    Epoprostenol
    Capsules
    dazoxiben
    Placebos
    Pharmaceutical Preparations

    Cite this

    Belch, J. J. ; Cormie, J. ; Newman, P. ; McLaren, M. ; Barbenel, J. ; Capell, H. ; Leiberman, P. ; Forbes, C. D. ; Prentice, C. R. / Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome : a double-blind trial. In: British Journal of Clinical Pharmacology. 1983 ; Vol. 15, No. S1. pp. 113S-116S.
    @article{6a2f460c91314df581bfbb86e088ddc4,
    title = "Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial",
    abstract = "1 UK-37248 (dazoxiben), an orally active thromboxane synthetase inhibitor, was evaluated in a double-blind trial of patients with severe Raynaud's syndrome. 2 Twenty patients were enrolled in the study. Eleven of these patients received dazoxiben 400 mg day and nine received matching placebo capsules. Treatment was given for 6 weeks and the patients reviewed at 2 weekly intervals during the study. 3 Assessment of response was judged by clinical symptoms and hand temperature measurements. Haematological and haemostatic studies were also carried out. 4 Results show a significant clinical improvement in patients receiving dazoxiben for six weeks. Hand temperature measurements, and haematological and haemostatic blood tests remained unchanged, however, apart from the expected lowering in plasma thromboxane B2 levels. 5 The mechanism of action of the drug would appear not to be mediated through increased prostacyclin production and further studies are under way to determine how improvement has been obtained in these patients.",
    author = "Belch, {J. J.} and J. Cormie and P. Newman and M. McLaren and J. Barbenel and H. Capell and P. Leiberman and Forbes, {C. D.} and Prentice, {C. R.}",
    year = "1983",
    doi = "10.1111/j.1365-2125.1983.tb02119.x",
    language = "English",
    volume = "15",
    pages = "113S--116S",
    journal = "British Journal of Clinical Pharmacology",
    issn = "0306-5251",
    publisher = "Wiley",
    number = "S1",

    }

    Belch, JJ, Cormie, J, Newman, P, McLaren, M, Barbenel, J, Capell, H, Leiberman, P, Forbes, CD & Prentice, CR 1983, 'Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial', British Journal of Clinical Pharmacology, vol. 15, no. S1, pp. 113S-116S. https://doi.org/10.1111/j.1365-2125.1983.tb02119.x

    Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome : a double-blind trial. / Belch, J. J.; Cormie, J.; Newman, P.; McLaren, M.; Barbenel, J.; Capell, H.; Leiberman, P.; Forbes, C. D.; Prentice, C. R.

    In: British Journal of Clinical Pharmacology, Vol. 15, No. S1, 1983, p. 113S-116S.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome

    T2 - a double-blind trial

    AU - Belch, J. J.

    AU - Cormie, J.

    AU - Newman, P.

    AU - McLaren, M.

    AU - Barbenel, J.

    AU - Capell, H.

    AU - Leiberman, P.

    AU - Forbes, C. D.

    AU - Prentice, C. R.

    PY - 1983

    Y1 - 1983

    N2 - 1 UK-37248 (dazoxiben), an orally active thromboxane synthetase inhibitor, was evaluated in a double-blind trial of patients with severe Raynaud's syndrome. 2 Twenty patients were enrolled in the study. Eleven of these patients received dazoxiben 400 mg day and nine received matching placebo capsules. Treatment was given for 6 weeks and the patients reviewed at 2 weekly intervals during the study. 3 Assessment of response was judged by clinical symptoms and hand temperature measurements. Haematological and haemostatic studies were also carried out. 4 Results show a significant clinical improvement in patients receiving dazoxiben for six weeks. Hand temperature measurements, and haematological and haemostatic blood tests remained unchanged, however, apart from the expected lowering in plasma thromboxane B2 levels. 5 The mechanism of action of the drug would appear not to be mediated through increased prostacyclin production and further studies are under way to determine how improvement has been obtained in these patients.

    AB - 1 UK-37248 (dazoxiben), an orally active thromboxane synthetase inhibitor, was evaluated in a double-blind trial of patients with severe Raynaud's syndrome. 2 Twenty patients were enrolled in the study. Eleven of these patients received dazoxiben 400 mg day and nine received matching placebo capsules. Treatment was given for 6 weeks and the patients reviewed at 2 weekly intervals during the study. 3 Assessment of response was judged by clinical symptoms and hand temperature measurements. Haematological and haemostatic studies were also carried out. 4 Results show a significant clinical improvement in patients receiving dazoxiben for six weeks. Hand temperature measurements, and haematological and haemostatic blood tests remained unchanged, however, apart from the expected lowering in plasma thromboxane B2 levels. 5 The mechanism of action of the drug would appear not to be mediated through increased prostacyclin production and further studies are under way to determine how improvement has been obtained in these patients.

    U2 - 10.1111/j.1365-2125.1983.tb02119.x

    DO - 10.1111/j.1365-2125.1983.tb02119.x

    M3 - Article

    C2 - 6337601

    VL - 15

    SP - 113S-116S

    JO - British Journal of Clinical Pharmacology

    JF - British Journal of Clinical Pharmacology

    SN - 0306-5251

    IS - S1

    ER -